Eric Jia-Sobota, Founder, Author at EverGlade - Page 5 of 12

Eric Jia-Sobota, Founder

Eric Jia-Sobota is the National Leader of EverGlade’s Consulting Practice and the Founder of the Company. Eric’s consulting experience spans almost two decades across a breadth of industries, including, Federal Contracting, Life Sciences, Nonprofit, Technology, Construction, Healthcare, and others.

Eric Jia-Sobota, Co-Founder
Close-up of Medical Ampoule Production Line at Modern Modern Pharmaceutical Factory. Glass Ampoules are being Filled. Medication Manufacturing Process.

DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation

Leave a Comment / All Posts, DTRA, Life Sciences / By

Reimagining the Future of Vaccines: DTRA’s RAVEN RFI The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO), has announced a new Request for Information (RFI) under the initiative titled Reimagining Available Vaccines and Envisioning Novelty (RAVEN). This RFI reflects DTRA’s responsibility to prepare the U.S. warfighter for current and emerging

DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation Read More »

The White House Initiatives

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety

Leave a Comment / All Posts, ARPA-H, BARDA, Life Sciences / By

Promoting Domestic Production of Critical Medicines The White House is pushing to see more state-of-the-art pharmaceutical manufacturing facilities within the United States to strengthen the supply of essential medicines. On May 5, 2025, the President signed an Executive Order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines.” The goal of this order is

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety Read More »

3D rendering of Lymphocytes

DoD Seeks Host-Directed Therapeutics to Counter Emerging Biological Threats

Leave a Comment / Agency, All Posts, CPE CBRND / By

A New Direction: Host-Directed, Not Pathogen-Specific Unlike traditional antivirals or antibiotics, host-directed therapeutics (HDTs) focus on modulating the patient’s immune response rather than targeting a specific pathogen. This “threat-agnostic” approach is especially promising in an era marked by evolving biological agents and unpredictable infectious threats. The DoD is particularly interested in repurposed FDA-approved therapeutics or

DoD Seeks Host-Directed Therapeutics to Counter Emerging Biological Threats Read More »

Chemical Threat Readiness

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes

Leave a Comment / DTRA, Life Sciences / By

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes April 2025 marks another pivotal moment for U.S. defense readiness in chemical and biological threat detection. Through the Medical CBRN Defense Consortium (MCDC), the Army Contracting Command has issued Solicitation RPP-25-04 seeking Enhanced White Papers for a groundbreaking prototype: the Assay Expansion for Chemical Diagnostic

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes Read More »

immunoassay IEID Lab Solicitation

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats

Leave a Comment / All Posts, BARDA, Life Sciences / By

Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure. BARDA’s RRPV initiative calls for laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats Read More »

The White House 2025 Executive Order

April 2025 Executive Order

Leave a Comment / Emerging Technologies / By

Key Takeaways from the April 2025 Executive Order On April 2, 2025, President Trump issued an Executive Order titled “Modernizing Defense Acquisitions and Spurring Innovation in the Defense Industrial Base.” This directive signals a major shift in how the Department of Defense (DoD) acquires technology, emphasizing speed, flexibility, and inclusion of non-traditional contractors. 1. Streamlining

April 2025 Executive Order Read More »

Double Helix Biotechnology

Charting the Future of Biotechnology

Leave a Comment / Emerging Technologies / By

NSCEB Final Report: Charting the Future of Biotechnology in America The National Security Commission on Emerging Biotechnology (NSCEB) has released its final report, “Charting the Future of Biotechnology: An Action Plan for American Security and Prosperity.” This document outlines a strategic roadmap emphasizing the need for the United States to significantly increase investment—recommending a minimum

Charting the Future of Biotechnology Read More »

Abstract background of Rotor turbine with several Turbine blades

DIU Launches Blue Manufacturing Marketplace

Leave a Comment / All Posts, DIU, Emerging Technologies / By

Strengthening America’s Defense: The Defense Innovation Unit’s Blue Manufacturing Initiative In an era where rapid technological advancement is crucial for national security, the Defense Innovation Unit (DIU) has launched the Blue Manufacturing Initiative. This strategic program aims tobolster the United States defense manufacturing capabilities by fostering partnerships with trustedadvanced manufacturing companies. Addressing Critical Challenges The

DIU Launches Blue Manufacturing Marketplace Read More »

PROSPR program

Proactive Solutions for Prolonging Resilience Opportunity Announcement

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

The Foci of PROSPR ARPA-H-SOL-25-125, PROSPR The PROSPR solicitation outlines a comprehensive, multi-year program structured around the development, validation, and deployment of novel health technologies. The program is divided into three primary technical areas (TAs), each addressing a critical component of healthspan extension: TA1 focuses on developing a PROSPR Intrinsic Capacity (IC) score that quantifies

Proactive Solutions for Prolonging Resilience Opportunity Announcement Read More »

organophosphorus nerve agents

Project UPREG

Leave a Comment / All Posts, DTRA, Life Sciences / By

Project UPREG: DTRA’s Push for Enhanced Protection Against Nerve Agents The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department, in its role as the Joint Science and Technology Office (JSTO), has launched Project UPREG, a bold initiative to develop next-generation medical countermeasures against organophosphorus nerve agents (OPNAs). These highly toxic compounds pose a

Project UPREG Read More »

avian flu vaccine

USDA Launches $100 Million Poultry Innovation Grand Challenge to Combat Avian Flu

Leave a Comment / All Posts / By

HPAI Innovation Notice Of Funding Opportunity (1) Poultry Innovation Grand Challenge Highly Pathogenic Avian Influenza (HPAI) has led to the culling of millions of birds, raised egg prices, and threatens the U.S. food supply, poultry producers, and agricultural economy worldwide. The U.S. Department of Agriculture (USDA) has announced a bold new initiative to combat HPAI,

USDA Launches $100 Million Poultry Innovation Grand Challenge to Combat Avian Flu Read More »

BARDA merge with ARPA-H

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures

Leave a Comment / All Posts, BARDA, Life Sciences / By

The U.S. Department of Health and Human Services (HHS) is undergoing one of the most significant structural transformations in its history. This realignment affects not only public health preparedness and biomedical innovation but also the broader operational framework, including funding mechanisms, programmatic leadership, and cross-agency coordination structures that supports millions of Americans across health care,

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures Read More »

Scroll to Top